The shingles vaccine market has experienced significant growth in recent years as more people seek to protect themselves from the painful and debilitating condition caused by reactivation of the varicella zoster virus (VZV), which also causes chickenpox. increase.
global Shingles Vaccine Market The 2021 valuation was approximately US$3.5 billion. With a projected CAGR of 13.9% over the next decade, the market could reach a valuation of around US$14.1 billion by the end of he 2032. The global shingles vaccine market is projected. We will witness an absolute investment opportunity growth of USD 10.2 billion between 2022 and 2032.
Request a Free Sample Report on “Herpes Zoster Vaccine Market”“@ https://www.persistencemarketresearch.com/samples/33198
The shingles vaccine is usually recommended for people over the age of 50 because the risk of developing shingles increases with age. However, the vaccine is also recommended for certain groups under the age of 50, such as those with weakened immune systems.
There are currently two shingles vaccines on the market: Xostavax and Singrix. Zostavax has been available to him for over a decade, but Shingrix was approved by the U.S. Food and Drug Administration (FDA) in 2017 and has quickly become the preferred choice due to its high efficacy rate.
enterprise
- GlaxoSmithKline
- Merck
- SK Chemicals
- Green Cross Co., Ltd.
- Gene One Life Science
- bakusitec
- CanSinoBIO
- Cipla Co., Ltd.
- Pfizer Japan Inc
Buy the full report now @ https://www.persistencemarketresearch.com/checkout/33198
In addition, aging population and increasing government initiatives to promote vaccination also contribute to the market growth. However, the high cost of vaccines and lack of reimbursement in some countries may hamper the market growth.
Overall, the shingles vaccine market is expected to continue growing over the next few years as more and more people seek to protect themselves from this painful and debilitating condition. It’s important to talk to your health care provider to determine.
Insights by Category
How is shingles accelerating the growth of the shingles vaccine market?
Shingles will have the fastest growth during the forecast period and is anticipated to achieve a growth rate of 14.4% during the forecast period set between 2022 and 2032. Those between the ages of 50 and 69. Based on CDC data, shingles was found to be 91% effective in preventing postherpetic neuralgia. The herpes zoster vaccine is used in immunization programs in several countries due to the decreasing rate of herpes zoster.
Customization request @ https://www.persistencemarketresearch.com/request-customization/33198
Key Segments Covered By Herpes Zoster Vaccines Industry Study
Shingles Vaccine Market by Product Type:
- Herpes zoster
- Zosta Bucks
- Skyzo Star
Shingles Vaccine Market by Vaccine Type:
- recombinant vaccine
- live attenuated vaccine
Shingles Vaccine Market by Region:
- North America Shingles Vaccine Market
- Latin American Shingles Vaccine Market
- European Shingles Vaccine Market
- South Asia Shingles Vaccine Market
- East Asian Shingles Vaccine Market
- Oceania Shingles Vaccine Market
- Middle East and Africa Shingles Vaccine Market
For more information on Premium Insights, please visit the following links:
Respiratory care equipment market
Peripheral vascular device market
Libyan dialysis machine market
Over-the-counter scar treatment market
about us
Persistence Market Research is a US-based full-service market research firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals & Materials, Technology & Media, Energy & Mining, Food & Beverages, Semiconductor & Electronics, Consumer Goods, Transportation & Transportation industries. The firm leverages its multi-disciplinary capabilities and talented team of analysts to share data that precisely addresses the business needs of its clients.
inquiry:
Sustainability market research
Japan
Sustainability market research
〒130-0013 1-2-1 Kinshi, Tokyo Arca Central Building 14F
Telephone 0800-222-1088
America
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
US Phone – +1-646-568-7751
USA – Canada Toll Free – +1 800-961-0353
Sales – [email protected]
